We are more than impressed by what has been achieved with our academic partners’ research results – clinical projects and much more. Here is a summary of highlights from the 2022/23 Review:
A broad and varied product pipeline
There are currently 19 therapeutic projects in 22 clinical trials, together with five diagnostic and medical technology products in clinical validation. The potential benefit for patients is immense. The Review provides all the details, key trends, practical examples and tips from experts whose projects have already reached the clinic, for all those who want to follow them.
Start-up and licensing business continues to thrive
Ascenion held equity in a total of 30 start-ups at the end of 2022. Five of these are new, and seven secured a total of EUR 57 million in financing in 2022. In the licensing and cooperations area, Ascenion negotiated a total of 40 revenue-generating agreements in 2022, some arising from long-term success stories and broad platform technologies that continue to offer new licensing opportunities. Selected examples are presented in the Review.
Income from commercialization doubled
Our partners raised over EUR 8 million from agreements mediated by Ascenion in 2022. This is almost twice as high as in previous year. Given the current pipeline and deal flow, we anticipate that – allowing for fluctuations typically seen in our business – we will be able to maintain this level.
We would like to thank our partners for the excellent collaboration, and hope you enjoy reading the Review!
See Annual Review